Aventis Builds U.S. Diabetes Portfolio On Strong Amaryl Performance
Aventis is building its U.S. diabetes franchise in the near term based on strong sales of the oral sulfonylurea Amaryl, Investor Relations Director Arvind Sood said during a conference call July 28.
You may also be interested in...
The regulatory pathway of gene-activated erythropoietin Dynepo is evidence that the product is not equivalent to Amgen's Epogen, Aventis Chief Scientific Officer Frank Douglas, MD/PhD, said July 18 in Boston federal court.
Health care organizations should delay their general influenza vaccination campaigns by a month for the 2000-2001 flu season due to anticipated delays in availability of vaccine or outright shortages, the Center for Disease Control & Prevention's Advisory Committee on Immunization Practices recommended at its June 21 meeting.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011